Roger Stoll, Norman Hardman, Jason Stein, John Gill, Steven Nichtberger, Reid Dulberger, Walt Good, Matt Michels, David Welsh, Jean-Francois Gimonet, Carlo Montagner, Rick Click, Lisa Guttman, B. Joseph White, Yoshihiko Hatanaka, Paul Willems, Yonnie Butl | GenomeWeb
Chelsea Therapeutics Adds Two Independent Directors to Its Board; Founding Director Resigns
 
Roger Stoll and Norman Hardman have been appointed to the board of directors of Chelsea Therapeutics International, a Charlotte, NC, biopharmaceutical company. Their appointments increase the number of the board’s independent directors to six and the board's total membership to seven.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.